Core Viewpoint - The company is expected to see a significant increase in net profit for 2025, with projections indicating a year-on-year growth of 384.26% to 443.88%, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [1] Group 1: Financial Performance - The projected net profit attributable to shareholders for 2025 is estimated to be between 162 million to 182 million yuan [1] - The company's stock prices surged, with A-shares rising over 18% to 78.75 yuan, and H-shares increasing over 43% to 63 Hong Kong dollars, both reaching new highs since their listing [1] Group 2: Market and Operational Factors - The growth in revenue is attributed to the continuous expansion in overseas markets and the recovery of the domestic biopharmaceutical sector [1] - The company maintains high gross margins due to its strong technological advantages, and operational efficiency has been enhanced through lean management practices [1]
港A异动丨业绩亮眼，百奥赛图AH股齐创历史新高